Search research articles
Contact Us
Filters
Showing results (41-50 of 45) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 45 results.
The British Journal of Dermatology
|
July 15, 2017
Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients
Y Teramoto, U Keim, A Gesierich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
K Spieth, R Kaufmann, R Dummer, et al.
Cancer Immunology, Immunotherapy : CII
|
April 19, 2021
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
H M Stege, M Haist, S Schultheis, et al.
ESMO Open
|
August 3, 2024
Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study
E Chatziioannou, L M Serna Higuita, S Kreft, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 26, 2020
The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force
C Garbe, K Peris, E Soura, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 45) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 45 results.
The British Journal of Dermatology
|
July 15, 2017
Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients
Y Teramoto, U Keim, A Gesierich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2008
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
K Spieth, R Kaufmann, R Dummer, et al.
Cancer Immunology, Immunotherapy : CII
|
April 19, 2021
Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
H M Stege, M Haist, S Schultheis, et al.
ESMO Open
|
August 3, 2024
Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study
E Chatziioannou, L M Serna Higuita, S Kreft, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 26, 2020
The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force
C Garbe, K Peris, E Soura, et al.
Page
of 5